Description

Trombonet (clopidogrel) Coated Tablets 0.075 g. №60

Ingredients

Active ingredient: Clopidogrel 0.075 g.
Other ingredients: Microcrystalline cellulose, lactose monohydrate, hydroxypropyl cellulose, colloidal anhydrous silica, magnesium stearate.

Dosage

Recommended dosage: Take one tablet daily or as directed by a healthcare professional. Do not exceed the recommended dose.

Indications

Trombonet (clopidogrel) coated tablets are indicated for the prevention of blood clots in individuals at risk for heart attacks or strokes.

Contraindications

Do not use Trombonet (clopidogrel) tablets if you are allergic to clopidogrel or any other ingredients in the product. Consult your doctor before use if you have a history of bleeding disorders.

Directions

Swallow the tablet whole with a glass of water. It can be taken with or without food. Do not crush or chew the tablet.

Scientific Evidence

Clopidogrel, the active ingredient in Trombonet tablets, is a platelet aggregation inhibitor that works by irreversibly binding to the P2Y12 receptor on platelets, preventing platelet activation and aggregation. This mechanism of action makes it an essential medication in preventing cardiovascular events in high-risk patients.

Additional Information

It is important to inform your healthcare provider about all medications, supplements, and medical conditions before starting clopidogrel therapy. Regular monitoring of blood parameters may be necessary during treatment.

Clinical trials have demonstrated the efficacy of clopidogrel in reducing the risk of cardiovascular events in patients with a history of myocardial infarction, stroke, or peripheral arterial disease. The drug has shown to significantly decrease the incidence of major cardiovascular events compared to placebo, making it a cornerstone in the management of atherosclerotic conditions.

Research published in the New England Journal of Medicine has highlighted the benefits of clopidogrel therapy in combination with aspirin in reducing the risk of recurrent cardiovascular events in patients with acute coronary syndromes. The dual antiplatelet therapy has been shown to improve outcomes and decrease mortality rates in this patient population.